يُسْمِي اللَّهُ الرَّحْمَنِ الرَّحِيمِ

قال تعالى

وَقَصَّيْ رَبِّكَ أَلَّا تَعْنِدُوا إِلَّا إِيَاهُ وَبَالْوَالِدِينِ إِخْسَانًا
إِمَّا يَبْلُغُونَ عَنْدَكَ الْكِبْرَ أَخْذُهَمَا أوُ كَلَّاهُمَا أَوَّ كَلَّاهُمَا قَلَّ
لَهُمَا أَفْ وَلَا تَنْهَرُهُمَا وَقُلْ لَهُمَا قُوَّلَا كَرِيمًا (23)
وَأَحْفِصْنَ لَهُمَا جَنَاحَ الدُّلِّ مِنَ الرَّحْمَةِ وَقُلْ رَبِّ
ارْحَمْهُمَا كَمَا رَحِيَّانِي صَغِيرًا (24)

صدق الله العظيم

سورة الإسراء الآيات 23-24
<table>
<thead>
<tr>
<th>Content</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dedication</td>
<td>1</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td></td>
</tr>
<tr>
<td>Abstract</td>
<td></td>
</tr>
<tr>
<td>المستخلص</td>
<td></td>
</tr>
<tr>
<td>Abbreviation</td>
<td></td>
</tr>
<tr>
<td>List of figure</td>
<td></td>
</tr>
<tr>
<td>List of tables</td>
<td></td>
</tr>
<tr>
<td>Chapter one Introduction &amp; literature review</td>
<td></td>
</tr>
<tr>
<td>1.1 Introduction</td>
<td></td>
</tr>
<tr>
<td>1.2 literature review</td>
<td></td>
</tr>
<tr>
<td>1.2.1 Normal Haemostasis</td>
<td></td>
</tr>
<tr>
<td>1.2.1.1 Normal Components of Haemostasis</td>
<td></td>
</tr>
<tr>
<td>1-2.1.1.1 Vascular tissue</td>
<td></td>
</tr>
<tr>
<td>1-2.1.1.2 Platelets</td>
<td></td>
</tr>
<tr>
<td>1-2.1.1.3 Coagulation System</td>
<td></td>
</tr>
<tr>
<td>1-2.1.1.4 Fibrinolytic System</td>
<td></td>
</tr>
<tr>
<td>1.2.1.2 Coagulation System Dysfunction in DM</td>
<td></td>
</tr>
<tr>
<td>1.2.1.3 Platelet Dysfunction in DM</td>
<td></td>
</tr>
<tr>
<td>1.2.1.4 Hemostasis Alteration in DM</td>
<td></td>
</tr>
<tr>
<td>1.2.1.5 Fibrinolytic alteration in DM</td>
<td></td>
</tr>
<tr>
<td>1.2.1.6 Fibrinogen and factor VIII alteration in DM</td>
<td></td>
</tr>
<tr>
<td>1.2.2 Diabetes mellitus</td>
<td></td>
</tr>
<tr>
<td>1.2.2.1 DM classifications</td>
<td></td>
</tr>
<tr>
<td>1.2.2.1.1 Type 1 Diabetes</td>
<td></td>
</tr>
<tr>
<td>1.2.2.1.2 Type 2 Diabetes</td>
<td></td>
</tr>
<tr>
<td>1.2.2.2 Complications of DM</td>
<td></td>
</tr>
<tr>
<td>1.2.2.2.1 Acute complications</td>
<td></td>
</tr>
<tr>
<td>1.2.2.2.2 Chronic complications</td>
<td></td>
</tr>
<tr>
<td>1.2.2.2.3 Potential Pathogenic Mechanisms of Diabetic Complications</td>
<td></td>
</tr>
<tr>
<td>1.3 Objectives</td>
<td></td>
</tr>
<tr>
<td>1.4 Rationale</td>
<td></td>
</tr>
<tr>
<td>Chapter two Material and methods</td>
<td></td>
</tr>
<tr>
<td>2.1 Study design</td>
<td></td>
</tr>
<tr>
<td>2.2 Study population</td>
<td></td>
</tr>
<tr>
<td>2.2.1 Inclusion Criteria</td>
<td></td>
</tr>
</tbody>
</table>
2.2.2 Exclusion Criteria
2.3 Sampling technique
2.4 Sample size
2.4 Data collection
2.6 Sample collection and treatment
2.7 Fibrinogen measurement
2.7-1 Test Principle
2.7-2 Procedures
2.7-3 Quality Control (QC)
2.8 Technique of factor viii assay
2.8-1 principle
2.8-2 procedure
2.8-3 Quality Control
2.8-4 EXPECTED VALUES
2.9 Ethical consideration
2.10 Data analysis

Chapter three Result

3 Results

Chapter four Discussion, conclusion, and recommendation

4.1 Discussion
4.2 Conclusion
4.3 Recommendation

References

Appendices
Appendix 1

Questionnaire

جامعة السودان للعلوم والتكنولوجيا
كلية علوم المختبرات الطبية
قسم أمراض الدم ومبحث المناعة الدموية

Name…………………………………………………………………..

Age…………………………………………………………………

Sex…………………………………………………………………

Do you have diabetes?  هل عندك مرض السكري؟

Yes ☐ NO ☐

What type of diabetes?  اي نوع من مرض السكري؟

Type IDM ☐ type II DM ☐ GDM ☐

Diabetic treatment  علاجات تستخدمها

Oral hypoglycemic drug OHG ☐ insulin ☐

OHG and insulin ☐ others…………..

Do you smoke?  هل تدخن

Yes ☐ NO ☐

Do you use other medication and specify هل تستخدم اي علاجات اخرى بإذنها

Result:-

Fibrinogen……………….mg\dl

Factor VIII……………….%
Appendix II

بسم الله الرحمن الرحيم

كلية الدراسات العليا برنامج ماجستير-مختبرات طبية
تخصص علم الدم
براءة اخلاقية

سوف يتم اخذ عينة من الدم (5مل) من الوريد بواسطة حقنة طعن وذلك بعد مسح منطقة اخذ العينة بواسطة المطهر. كل الادوات المستخدمة للأخذ العينة معقمة ومتبوع فيها كل وسائل السلامة العملية. وانا أقر بأن هذه العينات يتم تحليلها فقط لطلب البحث.

وافق أنا المذكور أعلاه علي اخذ عينة لأجراء الدراسة

الاسم: 

الامضاء: 

التاريخ:
Appendix III

2-9-3. Reagents

- Stago STA® Fibrinogen (for *in vitro* diagnostic use only) – contains lyophilized human calcium thrombin at a concentration of approximately 80 NIH unit/mL. Each vial was reconstituted with 5 mL of distilled water. Reconstituted material was incubating at room temperature (18° C - 25° C) for 30 minutes. After incubation, the solution was gently mixed by swirling the vial without creating bubbles. The reagent was handled and disposed as a biohazard.

- Control: Precision BioLogic CRYOcheck™ Pooled Normal Plasma: normal citrated human plasma from a minimum of 20 healthy individuals, buffered using Hepes buffer, aliquoted and rapidly frozen. Each vial was thawed (1.0 mL) at 37° C + 1° C in a waterbath for 4 minutes (1.0 mL) or 5 minutes (1.5 mL). Plasma was allowed to acclimate to room temperature (18 - 25° C) and inverted gently prior to use.

- Calibration Reference Plasma

- Distilled Water

- Owren’s-Koller (veronal) buffer – buffered solution at pH of 7.35. The manufacture instruction for disposal were followed to prevent formation of explosive metallic azides.

2-9-4. KIT Reagents

- **Reagent 1**: freeze dried titrated sodium calcium thrombin containing a specific heparin inhibitor.

- **Reagent 2**: Ready for use Owren-Koller buffer, pH 7.35 contains sodium azide as preservative.

2-9-6. Reagent preparation and storage
Reagent 1: Each vial was reconstituted with 2 ml of distilled water and allowed it to stand at room temperature (18-25 °C) for 30 minutes.

Reagent 2 was ready for use.

2-10-2 reagent
Factor VIII Deficient Substrate Plasma (Cat. No. 5193)
Ingredients: The reagent is human plasma which contains less than 1% Factor VIII activity. Precautions: For In-Vitro Diagnostic Use Only.
Preparation for Use: Each vial was Reconstituted of Factor VIII Deficient Substrate Plasma with 1.0 mL deionized water. Swirled gently and allowed to stand 15 minutes at room temperature to ensure complete dissolution.
Storage and Stability: The lyophilized product is stable until the expiration date printed on the vial and box labels when stored at 2 to 6°C. The reconstituted product is stable for 8 hours. After the initial reconstitution period, the product was kept on ice for the duration of testing.

Materials Provided:
Cat. No.
- Factor VIII Deficient Substrate Plasma 5193
- Other Supplies Available from Helena
- Helena APTT Reagent Kits
  - 10 x 5.0 mL - 250 tests 5383
  - 10 x 10 mL - 500 tests 5384
  - 10 x 10 mL - APTT Reagent 5385
10 x 10 mL - Calcium Chloride          5386
Helena APTT-SA Reagent Kits
10 x 10 mL - 500 tests             5389
10 x 10 mL - APTT-SA Reagent         5387
10 x 5 mL - 250 tests             5388

Materials required but not provided:
12 x 75 mm plastic test tubes
Stopwatch

Plastic or siliconized glass serological pipettes and syringes